相關(guān)產(chǎn)品
Claudin18.2 重組兔單克隆抗體
Specifications
- 產(chǎn)品注冊(cè)名稱
- 細(xì)胞緊密連接蛋白18.2（Claudin18.2）抗體試劑（免疫組織化學(xué)法）
- 目錄號(hào)
- I1241
- 克隆號(hào)
- BP6249
- 亞細(xì)胞定位
- 細(xì)胞膜
- 陽(yáng)性對(duì)照
- 胃
- 修復(fù)方式
- HIER
- 組織類型
- FFPE
- 規(guī)格
- 濃縮液：0.1mL/1mL 工作液：1.5mL/7mL
- 用途
- NMPA IVD
Applicable platform
- Biolynx平臺(tái)
- Leica平臺(tái)
- Roche平臺(tái)
- Dako平臺(tái)
Reference
1. Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer. [J] . Baek Jin Ho,Park Dong Jin,Kim Gyu Yeol,Cheon Jaekyung,Kang Byung Woog,Cha Hee Jeong,Kim Jong Gwang. Anticancer research . 2019 (12)
2. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study. [J] . Dottermusch Matthias,Krüger Sandra,Behrens
Hans-Michael,Halske Christine,R?cken Christoph. Virchows Archiv : an international journal of pathology . 2019 (5).
3. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. [J] . Rohde Christoph,Yamaguchi Rin,Mukhina Svetlana,Sahin Ugur,Itoh Kyogo,Türeci ?zlem. Japanese journal of clinical oncology . 2019 (9).
